Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-IMG-132950

Xenbase Image ID: 132950


Figure 6 Repressing and activating functions of Xvent-2. A, phenotypes of embryos (around st. 30) injected ventrally (a, b) or dorsally (c, d) with 1.5 ng of GAL4-AD/Xvent-2 RNA perblastomere at the four-cell stage. Note formation of a posterior double axis (arrowhead) at ventral and ventralization at dorsal injections. The insetin a shows an uninjected control embryo (all embryos are orientated with posterior to left and anterior to right). B,an intron 2/basal BMP-4 promoter/luciferase reporter construct is activated by co-injection with low amounts of GAL4-AD/Xvent-2 RNA into dorsal blastomeres of four-cell stage embryos. Higher amounts lead to reversal or even to inhibition, as shown by ventral co-injection with 1.5 ng of perblastomere. C, a yeast-based assay was used to determine the transactivatory efficiency of Xvent-1 and Xvent-2. Complete proteins were fused to the GAL4 DNA-binding domain and expressed in pAS2 under control of the ADH promoter. The recombinants were transfected into yeast strain Y187, thereby prompting an interaction between the GAL4 fusions and the genomic GAL1-binding site giving rise to the activation of the LacZ reporter. Efficiency of fusion protein synthesis was controlled by immunoblotting of yeast extracts using monoclonal hemagglutinin antibodies. The enzymatic activity of LacZ was determined after 1 h in arbitrary units relative to the activatory strength of the GAL-4 activation domain.

Image published in: Schuler-Metz A et al. (2000)

Copyright © 2000. Image reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.

Larger Image
Printer Friendly View

Return to previous page